Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Jun 9, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat advanced ovarian, fallopian tube, or peritoneal cancer by using a method called hyperthermic intraperitoneal chemotherapy (HIPEC) with a drug called cisplatin. The trial is comparing the effects of administering this heated chemotherapy during surgery versus before surgery. The goal is to see if this approach can effectively kill more cancer cells and improve patient outcomes compared to standard treatments.

To be eligible for this trial, participants should be adults over 18 with newly diagnosed stage III or IV cancer, who are also receiving chemotherapy before surgery. They should be fit for major surgery and meet specific health criteria. If someone joins the trial, they can expect to undergo surgery with either the heated chemotherapy during the procedure or receive it beforehand. The trial is currently recruiting participants, and it aims to better understand the best ways to use this treatment to help patients with these challenging cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand (English-speaking), and willingness to sign a written, informed consent
• • Age \> 18 years old
• * Newly diagnosed stage III or IV epithelial (serous, mucinous, or endometrioid) ovarian, fallopian tube or peritoneal cancer diagnosed by:
• • Biopsy/histology (either by interventional radiology or laparoscopy) OR
• * Cytology; If diagnosis is based on cytology the following criteria must be met:
• • Immunohistochemistry on the block from cytology to demonstrate Mullerian origin
• • Presence of pelvic mass AND CA 125 \> 200kU/I AND CA125/CEA ratio \> 25 at initial diagnosis
• • Omental cake or other metastases larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size (diagnosed by computed tomography \[CT\]/magnetic resonance imaging \[MRI\], ultrasound, or laparoscopy)
• • Patient planned for or currently receiving neoadjuvant chemotherapy due to the fact that optimal primary CRS was determined not to be feasible by the primary surgeon
• • Patient must be planned or scheduled to undergo interval cytoreductive surgery after cycle 3-4 of neoadjuvant surgery
• • Completion of three cycles of neoadjuvant chemotherapy (NACT) with standard therapy (carboplatin \[area under the curve (AUC) 5-6\] day \[D\]1 + paclitaxel \[175 mg/m\^2\] D1 every 3 weeks)
• • Following 3-4 cycles of NACT partial or complete response
• • Following 3-4 cycles of NACT at least 50% decrease in CA-125 level between pre-cycle 1 and post-cycle 3/prior to surgery
• • Fit for major surgery, American Society of Anesthesiologists (ASA )1 or ASA 2
• • Eastern Cooperative Oncology Group (ECOG) performance-status score of 0-2
• • Serum creatinine \< 1.4 mg/dL
• • Creatinine clearance \> 60 ml/min (Cockcroft-Gault formula)
• • White blood cell count \> 3.5 x 10\^9 cells/L
• • Absolute neutrophil count \> 1.5 kg/ul
• • Platelets \> 100,000/ul
• • Total bilirubin within 1.5 x normal institutional limits
• • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x institutional upper limit of normal
• • For quality of life assessment, baseline questionnaires should be filled in before randomization
• Exclusion Criteria:
• • History of breast cancer or previous malignancy within 5 years prior to inclusion, with the exception of radically excised basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• • Low grade serious carcinoma of the ovary or borderline ovarian tumors
• • History or current diagnosis of inflammatory bowel disease
• • History of allergic reactions to compounds of similar chemical or biologic composition to cisplatin, carboplatin, and paclitaxel
• • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
• • Patients in whom an optimal or complete cytoreduction cannot be performed will be excluded at the time of surgery and be replaced